GlaxoSmithKline chief executive Andrew Witty has been appointed at as the lead non-executive board member at the Department for Business, Innovation and Skills.
Witty takes up his position on the new departmental board from January 1 and will be tasked with helping to create policy by utilizing his professional experience. “I am delighted to have been asked to take on this role,” said Witty. “I look forward to working with BIS and the Secretary of State to build…
This content is for subscribers only. Subscribe now for free to read the full article.
Already a subscriber? Login
